PMV Pharmaceuticals, Inc.

NasdaqGS:PMVP Stock Report

Market Cap: US$66.7m

PMV Pharmaceuticals Future Growth

Future criteria checks 2/6

PMV Pharmaceuticals is forecast to grow earnings and revenue by 13.7% and 62% per annum respectively while EPS is expected to grow by 32.3% per annum.

Key information

13.7%

Earnings growth rate

32.30%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate62.0%
Future return on equityn/a
Analyst coverage

Low

Last updated08 Jul 2026

Recent future growth updates

Recent updates

Analysis Article • May 19

PMV Pharmaceuticals (NASDAQ:PMVP) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jan 28

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jun 11

Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 04

Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Dec 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 08

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • May 10

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 11

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 22

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 09

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals press release (NASDAQ:PMVP): Q2 GAAP EPS of -$0.38 beats by $0.04. cash equivalents, and marketable securities of $277.4m
Seeking Alpha • Jul 18

PMV Pharma joins Merck to study lead candidate with Keytruda

Cancer-focused biotech PMV Pharmaceuticals (NASDAQ:PMVP) announced an agreement with Merck (MRK) on Monday to study its lead product candidate PC14586 in combination with Merck’s (MRK) anti-PD-1 therapy Keytruda in advanced solid tumors. Accordingly, PMV (PMVP) will add a combination arm to study the experimental drug in the company’s ongoing Phase 1/2 PYNNACLE trial for patients with advanced solid tumors. The combination arm, designed to assess PC14586/ Keytruda combo in patients with advanced solid tumors harboring a p53 Y220C mutation, is expected to recruit about 36 subjects. Per the terms, PMV Pharma (PMVP) will sponsor the study, and Merck (MRK) will supply Keytruda. PC14586 is an investigational small molecule designed to selectively target the p53 Y220C mutation of cancers. Read: PMV (PMVP) traded lower last month after the company announced early data from the PYNNACLE trial for PC14586.
Analysis Article • Jun 09

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 05

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 23

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Apr 09

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Dec 25

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

Every investor in PMV Pharmaceuticals, Inc. ( NASDAQ:PMVP ) should be aware of the most powerful shareholder groups...

Earnings and Revenue Growth Forecasts

NasdaqGS:PMVP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202826-83-68-583
12/31/20273-92-83-774
12/31/2026N/A-81-68-714
3/31/2026N/A-78-75-75N/A
12/31/2025N/A-78-74-74N/A
9/30/2025N/A-83-73-73N/A
6/30/2025N/A-81-70-70N/A
3/31/2025N/A-61-53-53N/A
12/31/2024N/A-59-52-51N/A
9/30/2024N/A-51-48-47N/A
6/30/2024N/A-49-46-46N/A
3/31/2024N/A-65-58-57N/A
12/31/2023N/A-69-57-56N/A
9/30/2023N/A-73-61-59N/A
6/30/2023N/A-74-64-60N/A
3/31/2023N/A-74-68-61N/A
12/31/2022N/A-73-72-64N/A
9/30/2022N/A-72-67-60N/A
6/30/2022N/A-69-61-56N/A
3/31/2022N/A-65-54-52N/A
12/31/2021N/A-58-48-47N/A
9/30/2021N/A-50-46-45N/A
6/30/2021N/A-44-41-40N/A
3/31/2021N/A-39-38-38N/A
12/31/2020N/A-34-33-33N/A
9/30/2020N/A-31-28-28N/A
6/30/2020N/A-28-26-26N/A
3/31/2020N/A-27-25-25N/A
12/31/2019N/A-25N/A-22N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PMVP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PMVP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PMVP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PMVP's revenue (62% per year) is forecast to grow faster than the US market (12.8% per year).

High Growth Revenue: PMVP's revenue (62% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PMVP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 22:20
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PMV Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Gum-Ming LoweCraig-Hallum Capital Group LLC
Joshua SchimmerEvercore ISI